CG Oncology (CGON) Fundamental Analysis: Revenue, Earnings & Valuation

5.77 / 10

Netural

Fundamentally, CGON scores 5.8/10, reflecting average strength. Positive factors include fixed‑asset turnover and interest‑coverage ratios, while income‑tax‑to‑profit and receivables turnover lag. Overall, the fundamentals warrant a moderate stance amid mixed metric signals.

Analysis Checks(6/10)

Revenue-MV

Value-5.09

Score1/3

Weight20.77%

1M Return5.06%

Total operating revenue (YoY growth rate %)

Value254.70

Score1/3

Weight-4.77%

1M Return-1.40%

Inventory turnover ratio

Value5.94

Score3/3

Weight-2.23%

1M Return-0.67%

Accounts receivable turnover ratio

Value11.74

Score1/3

Weight-5.54%

1M Return-1.57%

PB-ROE

Value2.93

Score2/3

Weight43.92%

1M Return8.98%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-5.01%

1M Return-1.54%

Fixed assets turnover ratio

Value0.40

Score2/3

Weight-3.51%

1M Return-1.01%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-2.49%

1M Return-0.73%

Cost of sales ratio (%)

Value115.02

Score2/3

Weight-2.44%

1M Return-0.74%

Asset-MV

Value-0.55

Score3/3

Weight61.29%

1M Return13.09%

Is CGON undervalued or overvalued?

CGON scores 5.77/10 on fundamentals and holds a Fair valuation at present. Backed by its -21.67% ROE, -3985.02% net margin, -33.89 P/E ratio, 7.25 P/B ratio, and -47.52% earnings growth, these metrics solidify its Netural investment rating.